Drugs & Targets Dana-Farber, Gustave Roussy, L’Institut Servier sign oncology cooperation agreement June 10, 2022Vol.48 No.23
Drugs & Targets FDA campaign aims to prevent e-cigarette use among AI/AN youth June 10, 2022Vol.48 No.23
Drugs & Targets FDA approves two Opdivo-based regimens in unresectable advanced or metastatic ESCC June 03, 2022Vol.48 No.22
Drugs & Targets FDA approves Kymriah in relapsed or refractory follicular lymphoma June 03, 2022Vol.48 No.22
Drugs & Targets FDA grants priority review to Omblastys in pediatric CNS/leptomeningeal metastasis from neuroblastoma June 03, 2022Vol.48 No.22
Drugs & Targets FDA grants Fast Track designation to PDS0101 + Keytruda in recurrent or metastatic HPV16-positive HNC June 03, 2022Vol.48 No.22
Drugs & Targets OncoHealth, Blue Note Therapeutics partner to provide a digital therapeutic for cancer-related anxiety and depression June 03, 2022Vol.48 No.22
Drugs & Targets C2i Genomics, Karkinos Healthcare partner to bring AI-powered cancer R&D to India June 03, 2022Vol.48 No.22
